Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. more
Time Frame | SAVA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.82% | -2.82% | -0.37% |
1-Month Return | -89.42% | -4.22% | 1.26% |
3-Month Return | -90.12% | -9.52% | 8.14% |
6-Month Return | -85.37% | -3.45% | 11.66% |
1-Year Return | -90.49% | 5.62% | 30.23% |
3-Year Return | -93.78% | 3.8% | 29.52% |
5-Year Return | 48.4% | 39.68% | 90.73% |
10-Year Return | -78.57% | 105.02% | 201.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | (1.80K) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.57M | 346.00K | 534.00K | 1.30M | 89.42M | [{"date":"2019-12-31","value":1.75,"profit":true},{"date":"2020-12-31","value":0.39,"profit":true},{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":1.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.57M) | (346.00K) | (534.00K) | (1.80K) | (89.42M) | [{"date":"2019-12-31","value":-156800000,"profit":false},{"date":"2020-12-31","value":-34600000,"profit":false},{"date":"2021-12-31","value":-53400000,"profit":false},{"date":"2022-12-31","value":-180000,"profit":false},{"date":"2023-12-31","value":-8942300000,"profit":false}] |
Gross Margin | - | - | - | 100.00% | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.96M | 6.79M | 32.87M | 80.02M | 105.96M | [{"date":"2019-12-31","value":4.68,"profit":true},{"date":"2020-12-31","value":6.41,"profit":true},{"date":"2021-12-31","value":31.02,"profit":true},{"date":"2022-12-31","value":75.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.96M) | (6.45M) | (32.87M) | (80.02M) | (105.96M) | [{"date":"2019-12-31","value":-495900000,"profit":false},{"date":"2020-12-31","value":-644600000,"profit":false},{"date":"2021-12-31","value":-3286800000,"profit":false},{"date":"2022-12-31","value":-8002000000,"profit":false},{"date":"2023-12-31","value":-10595700000,"profit":false}] |
Total Non-Operating Income/Expense | 656.00K | 570.00K | 532.00K | 6.55M | 16.57M | [{"date":"2019-12-31","value":3.96,"profit":true},{"date":"2020-12-31","value":3.44,"profit":true},{"date":"2021-12-31","value":3.21,"profit":true},{"date":"2022-12-31","value":39.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.63M) | (6.33M) | (32.38M) | (76.25M) | (97.22M) | [{"date":"2019-12-31","value":-463100000,"profit":false},{"date":"2020-12-31","value":-633400000,"profit":false},{"date":"2021-12-31","value":-3238500000,"profit":false},{"date":"2022-12-31","value":-7624600000,"profit":false},{"date":"2023-12-31","value":-9721700000,"profit":false}] |
Income Taxes | (386.00K) | (480.00K) | (583.00K) | (3.77M) | - | [{"date":"2019-12-31","value":-38600000,"profit":false},{"date":"2020-12-31","value":-48000000,"profit":false},{"date":"2021-12-31","value":-58300000,"profit":false},{"date":"2022-12-31","value":-377400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (4.25M) | (5.85M) | (31.80M) | (72.47M) | - | [{"date":"2019-12-31","value":-424500000,"profit":false},{"date":"2020-12-31","value":-585400000,"profit":false},{"date":"2021-12-31","value":-3180200000,"profit":false},{"date":"2022-12-31","value":-7247200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (4.63M) | (6.33M) | (32.38M) | (76.25M) | (97.22M) | [{"date":"2019-12-31","value":-463100000,"profit":false},{"date":"2020-12-31","value":-633400000,"profit":false},{"date":"2021-12-31","value":-3238500000,"profit":false},{"date":"2022-12-31","value":-7624600000,"profit":false},{"date":"2023-12-31","value":-9721700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.25M) | (5.85M) | (31.80M) | (72.47M) | (97.22M) | [{"date":"2019-12-31","value":-424500000,"profit":false},{"date":"2020-12-31","value":-585400000,"profit":false},{"date":"2021-12-31","value":-3180200000,"profit":false},{"date":"2022-12-31","value":-7247200000,"profit":false},{"date":"2023-12-31","value":-9721700000,"profit":false}] |
EPS (Diluted) | (0.26) | (0.25) | (0.81) | (1.90) | (2.32) | [{"date":"2019-12-31","value":-26,"profit":false},{"date":"2020-12-31","value":-25,"profit":false},{"date":"2021-12-31","value":-81,"profit":false},{"date":"2022-12-31","value":-190,"profit":false},{"date":"2023-12-31","value":-232,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SAVA | |
---|---|
Cash Ratio | 2.61 |
Current Ratio | 3.55 |
Quick Ratio | 3.79 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SAVA | |
---|---|
ROA (LTM) | -45.60% |
ROE (LTM) | -10.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SAVA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SAVA | |
---|---|
Trailing PE | NM |
Forward PE | 151.52 |
P/S (TTM) | 0.00 |
P/B | 0.82 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Cassava Sciences Inc (SAVA) share price today is $2.765
Yes, Indians can buy shares of Cassava Sciences Inc (SAVA) on Vested. To buy Cassava Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SAVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cassava Sciences Inc (SAVA) via the Vested app. You can start investing in Cassava Sciences Inc (SAVA) with a minimum investment of $1.
You can invest in shares of Cassava Sciences Inc (SAVA) via Vested in three simple steps:
The 52-week high price of Cassava Sciences Inc (SAVA) is $42.2. The 52-week low price of Cassava Sciences Inc (SAVA) is $2.71.
The price-to-earnings (P/E) ratio of Cassava Sciences Inc (SAVA) is
The price-to-book (P/B) ratio of Cassava Sciences Inc (SAVA) is 0.82
The dividend yield of Cassava Sciences Inc (SAVA) is 0.00%
The market capitalization of Cassava Sciences Inc (SAVA) is $137.11M
The stock symbol (or ticker) of Cassava Sciences Inc is SAVA